Aims Proton pump inhibitors (PPIs) are often prescribed to prevent or treat gastrointestinal
disease. Whether the combination of systemic antitumour therapy and PPIs leads to poor …

We performed a systematic review and meta-analysis to evaluate the role of gastric acid
suppressant use on outcomes of tyrosine kinase inhibitors (TKIs) and oral chemotherapy …

Lectin is a carbohydrate-binding protein that recognizes specific cells by binding to cell-
surface polysaccharides. Tumor cells generally show various glycosylation patterns, making …

Purpose Concurrent proton pump inhibitor (PPI) use might reduce the plasma concentration
of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the …

Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …

Purpose Although imatinib-induced hepatotoxicity may aggravate the patient's clinical
condition and alter the treatment plan, the underlying mechanism of and factors influencing …

Background The use of gastric acid suppressants (GASs) has an influence on the exposure
of some epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and …

Background Multikinase inhibitors (MKI) are targeted molecular agents that have
revolutionized cancer management. However, there is a paucity of data concerning MKI …

Background: Although nilotinib hepatotoxicity can cause severe clinical conditions and may
alter treatment plans, risk factors affecting nilotinib-induced hepatotoxicity have not been …

Purpose Although several studies have examined tyrosine kinase inhibitor (TKI)-induced
hepatotoxicity, the majority of patients in those studies displayed low-grade (grade I–II) …